Literature DB >> 8904934

Circulating endothelin-1 levels in type 2 diabetic patients with ischaemic heart disease.

M Donatelli1, E Hoffmann, I Colletti, G Andolina, V Russo, M L Bucalo, T M Valenti, V Compagno, M G Cataldo, M L Morici.   

Abstract

To investigate whether circulating endothelin-1 (Et-1) may be related to the increased incidence and severity of ischaemic heart disease in type 2 diabetes mellitus, we compared the concentrations in type 2 diabetic patients and in non-diabetic patients with coronary artery disease (CAD) angiographically documented. Plasma levels of Et-1 were determined in 34 type 2 diabetic patients with CAD (16 with stable angina, 6 with unstable angina, 12 with previous myocardial infarction) and in 19 nondiabetic patients with CAD (4 with stable angina, 5 with unstable angina, 10 with previous myocardial infarction). Fifteen diabetic patients without CAD and 9 healthy volunteers served as control subjects. In the type 2 diabetic patients, the mean Et-1 levels were 3.19 +/- 1.61 pmol/l in those with stable angina, 3.58 +/- 1.92 pmol/l in those with unstable angina, 4.24 +/- 2.53 pmol/l in those with myocardial infarction. These values were not significantly different one another, nor from the values obtained from type 2 diabetic controls (3.64 +/- 2.13 pmol/l). In the non-diabetic patients, the mean Et-1 levels were 3.92 +/- 0.73 pmol/l in those with stable angina, 4.35 +/- 1.67 pmol/l in those with unstable angina, 4.33 +/- 1.66 pmol/l in those with myocardial infarction. These values were not significantly different one another, but significantly higher than those obtained from healthy controls (2.07 +/- 0.67 pmol/l; P < 0.001). No significant differences were found in Et-1 levels between diabetic and non-diabetic patients with stable, unstable angina and previous myocardial infarction. In contrast, a statistically significant difference was found in Et-1 levels between diabetic and non-diabetic control subjects (P < 0.05). In conclusion, similar raised concentrations of Et-1 in diabetic and non-diabetic patients with stable, unstable angina and previous myocardial infarction do not support the hypothesis that higher levels of Et-1 in diabetic patients are responsible for the increased incidence of CAD in diabetes mellitus. However, the raised Et-1 levels found in diabetic patients in the absence of CAD strongly suggest that a generalised endothelial dysfunction, documented in our study by increased levels of Et-1, most probably precedes subsequent cardiovascular diseases.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8904934     DOI: 10.1007/bf02048552

Source DB:  PubMed          Journal:  Acta Diabetol        ISSN: 0940-5429            Impact factor:   4.280


  13 in total

Review 1.  George Lyman Duff Memorial Lecture. Atherogenesis in diabetes.

Authors:  E L Bierman
Journal:  Arterioscler Thromb       Date:  1992-06

2.  Plasma endothelin levels in NIDDM patients with macroangiopathy.

Authors:  M Donatelli; I Colletti; M L Bucalo; V Russo; S Verga
Journal:  Diabetes Res       Date:  1994

3.  Threshold concentrations of endothelin-1 potentiate contractions to norepinephrine and serotonin in human arteries. A new mechanism of vasospasm?

Authors:  Z H Yang; V Richard; L von Segesser; E Bauer; P Stulz; M Turina; T F Lüscher
Journal:  Circulation       Date:  1990-07       Impact factor: 29.690

4.  5-year incidence of atherosclerotic vascular disease in relation to general risk factors, insulin level, and abnormalities in lipoprotein composition in non-insulin-dependent diabetic and nondiabetic subjects.

Authors:  M I Uusitupa; L K Niskanen; O Siitonen; E Voutilainen; K Pyörälä
Journal:  Circulation       Date:  1990-07       Impact factor: 29.690

5.  Endothelin stimulates c-fos and c-myc expression and proliferation of vascular smooth muscle cells.

Authors:  I Komuro; H Kurihara; T Sugiyama; M Yoshizumi; F Takaku; Y Yazaki
Journal:  FEBS Lett       Date:  1988-10-10       Impact factor: 4.124

6.  Endothelin is a potent mitogen for rat vascular smooth muscle cells.

Authors:  Y Hirata; Y Takagi; Y Fukuda; F Marumo
Journal:  Atherosclerosis       Date:  1989-08       Impact factor: 5.162

7.  Diabetes, fibrinogen, and risk of cardiovascular disease: the Framingham experience.

Authors:  W B Kannel; R B D'Agostino; P W Wilson; A J Belanger; D R Gagnon
Journal:  Am Heart J       Date:  1990-09       Impact factor: 4.749

8.  Urinary albumin excretion, cardiovascular disease, and endothelial dysfunction in non-insulin-dependent diabetes mellitus.

Authors:  C D Stehouwer; J J Nauta; G C Zeldenrust; W H Hackeng; A J Donker; G J den Ottolander
Journal:  Lancet       Date:  1992-08-08       Impact factor: 79.321

9.  Endothelium-mediated coronary blood flow modulation in humans. Effects of age, atherosclerosis, hypercholesterolemia, and hypertension.

Authors:  A M Zeiher; H Drexler; B Saurbier; H Just
Journal:  J Clin Invest       Date:  1993-08       Impact factor: 14.808

10.  Presence of immunoreactive endothelin in human plasma.

Authors:  K Ando; Y Hirata; M Shichiri; T Emori; F Marumo
Journal:  FEBS Lett       Date:  1989-03-13       Impact factor: 4.124

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.